

AstraZeneca plans to invest \$50 B in America for medicines manufacturing and R&D

22 July 2025 | News

Investment will support AstraZeneca's ambition to reach \$80 billion revenue by 2030



AstraZeneca has announced \$50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.

The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the \$3.5 billion announced in November 2024.

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.

The \$50 billion investment across R&D and manufacturing footprint in the US over the next five years also includes:

- Expansion of R&D facility in Gaithersburg, Maryland
- State-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
- Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California
- · Continuous manufacturing expansion in Mount Vernon, Indiana
- Specialty manufacturing expansion in Coppell, Texas
- New sites to supply clinical trials
- · Growing research and development investment in novel medicines

Collectively, these investments will help deliver AstraZeneca's ambition of reaching \$80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.